Literature DB >> 16605285

Productivity costs in health-state valuations : does explicit instruction matter?

Marieke Krol1, Werner Brouwer, Pedram Sendi.   

Abstract

BACKGROUND: There has been considerable debate on whether productivity costs should be captured in the numerator or the denominator of the cost-effectiveness ratio. That debate cannot be resolved on the basis of theoretical arguments alone because the final choice also depends on what is incorporated in health-state valuations by respondents and how this influences outcomes. At the moment, little is known about whether the effects of ill health on income are included in health-state valuations, and how instructions on including or excluding the effects on income influence health-state valuations. AIM: To conduct an empirical study of health-state valuations to test: (i) whether or not respondents spontaneously include the effect of ill health on income and leisure time; (ii) the impact on the valuation of inclusion (or exclusion) of such effects; and (iii) the influence of explicit instructions on this matter.
METHODS: Three questionnaires were developed and administered to the general public. Health-state valuations were conducted by visual analogue scale scoring of three health states of differing severity taken from the EQ-5D. Version 1 had no directions regarding inclusion/exclusion of effects of ill health on income. Those respondents who spontaneously included effects on income were subsequently asked to value the same three health states again, excluding these effects. Version 2 had explicit instructions to incorporate the effects on income. Version 3 stated that income was assumed to not change as a result of ill health. Respondents for versions 2 and 3 were also questioned about inclusion of effects on leisure time.
RESULTS: Giving explicit instructions on the incorporation or exclusion of effects of ill health on income did not lead to significant differences in subsequent health-state valuations. In the absence of instruction, 36% of respondents included and 64% excluded effects on income, but the health-state valuations of the two groups were not significantly different. Eighty-four percent of respondents included the effects of ill health on leisure activities, and again this had no significant impact on the resulting health-state valuations.
CONCLUSIONS: It appears that neither spontaneous differences in incorporation of effects on income, nor explicit instructions will yield significantly different health-state valuations. This may suggest that QALY measures are insensitive to concerns regarding effects on income even when these are (explicitly) incorporated, and these effects may therefore be best placed on the cost side of the cost-effectiveness ratio.

Mesh:

Year:  2006        PMID: 16605285     DOI: 10.2165/00019053-200624040-00009

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  20 in total

1.  Inconsistencies in the "societal perspective" on costs of the Panel on Cost-Effectiveness in Health and Medicine.

Authors:  D Meltzer; M Johannesson
Journal:  Med Decis Making       Date:  1999 Oct-Dec       Impact factor: 2.583

2.  Visual analog scales: do they have a role in the measurement of preferences for health states?

Authors:  G W Torrance; D Feeny; W Furlong
Journal:  Med Decis Making       Date:  2001 Jul-Aug       Impact factor: 2.583

3.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

4.  Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel.

Authors:  W B Brouwer; M A Koopmanschap; F F Rutten
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

5.  The friction cost method for measuring indirect costs of disease.

Authors:  M A Koopmanschap; F F Rutten; B M van Ineveld; L van Roijen
Journal:  J Health Econ       Date:  1995-06       Impact factor: 3.883

6.  Is silence golden? A test of the incorporation of the effects of ill-health on income and leisure in health state valuations.

Authors:  Pedram Sendi; Werner B F Brouwer
Journal:  Health Econ       Date:  2005-06       Impact factor: 3.046

Review 7.  The relationship between productivity and health-related QOL: an exploration.

Authors:  Werner B F Brouwer; Willem-Jan Meerding; Leida M Lamers; Johan L Severens
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

8.  Leisure time in economic evaluation: theoretical and practical considerations.

Authors:  Pedram Sendi; Werner Brouwer
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2004-02       Impact factor: 2.217

9.  Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion.

Authors:  W B Brouwer; M A Koopmanschap; F F Rutten
Journal:  Health Econ       Date:  1997 Sep-Oct       Impact factor: 3.046

10.  Productivity costs, time costs and health-related quality of life: a response to the Erasmus Group.

Authors:  M C Weinstein; J E Siegel; A M Garber; J Lipscomb; B R Luce; W G Manning; G W Torrance
Journal:  Health Econ       Date:  1997 Sep-Oct       Impact factor: 3.046

View more
  10 in total

1.  Does the EQ-5D reflect lost earnings?

Authors:  Carl Tilling; Marieke Krol; Aki Tsuchiya; John Brazier; Job van Exel; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2012-01       Impact factor: 4.981

2.  Thirty down, only ten to go?! Awareness and influence of a 10-year time frame in TTO.

Authors:  F E van Nooten; X Koolman; J J V Busschbach; W B F Brouwer
Journal:  Qual Life Res       Date:  2013-08-14       Impact factor: 4.147

Review 3.  Cost effectiveness of medication adherence-enhancing interventions: a systematic review of trial-based economic evaluations.

Authors:  Edwin J M Oberjé; Reina J A de Kinderen; Silvia M A A Evers; Cees M J van Woerkum; Marijn de Bruin
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

Review 4.  Productivity costs in economic evaluations: past, present, future.

Authors:  Marieke Krol; Werner Brouwer; Frans Rutten
Journal:  Pharmacoeconomics       Date:  2013-07       Impact factor: 4.981

5.  How to estimate productivity costs in economic evaluations.

Authors:  Marieke Krol; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

Review 6.  Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders.

Authors:  Marieke Krol; Jocé Papenburg; Marc Koopmanschap; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

7.  Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.

Authors:  Pedram Sendi; Huldrych F Günthard; Mathew Simcock; Bruno Ledergerber; Jörg Schüpbach; Manuel Battegay
Journal:  PLoS One       Date:  2007-01-24       Impact factor: 3.240

8.  What were they thinking when providing preference measurements for generic health states? The evidence for HUI3.

Authors:  David Feeny; William Furlong; George W Torrance
Journal:  Health Qual Life Outcomes       Date:  2018-08-15       Impact factor: 3.186

9.  Cost-effectiveness of one year dementia follow-up care by memory clinics or general practitioners: economic evaluation of a randomised controlled trial.

Authors:  Els Meeuwsen; René Melis; Geert van der Aa; Gertie Golüke-Willemse; Benoit de Leest; Frank van Raak; Carla Schölzel-Dorenbos; Desiree Verheijen; Frans Verhey; Marieke Visser; Claire Wolfs; Eddy Adang; Marcel Olde Rikkert
Journal:  PLoS One       Date:  2013-11-25       Impact factor: 3.240

10.  A cross-sectional survey of work and income loss consideration among patients with herpes zoster when completing a quality of life questionnaire.

Authors:  Kelly D Johnson; Susan K Brenneman; Chrisann Newransky; Seth Sheffler-Collins; Laura K Becker; Angela Belland; Camilo J Acosta
Journal:  BMC Health Serv Res       Date:  2018-08-25       Impact factor: 2.655

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.